Bills in Congress Would Increase Access to Generics
Bills in Congress Would Increase Access to Generics Javascript must be enabled to use this site. Please enable Javascript in your browser and try again. × Search search POPULAR SEARCHES SUGGESTED LINKS Join AARP for just $9 per year when you sign up for a 5-year term. Get instant access to members-only products and hundreds of discounts, a free second membership, and a subscription to AARP the Magazine. Leaving AARP.org Website You are now leaving AARP.org and going to a website that is not operated by AARP. A different privacy policy and terms of service will apply.
The Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act targets anticompetitive behavior by brand-name drugmakers that inhibits the development of competing generics. This bill has been introduced in both the House of Representatives and the Senate. Get instant access to members-only products and hundreds of discounts, a free second membership, and a subscription to AARP the Magazine. A separate measure would end the use of so-called pay-for-delay deals in which brand-name companies pay generic manufacturers to delay launching a lower-priced version of their product. “AARP has made expanding access to generics one of our federal priorities in our prescription drug campaign,” says Megan O’Reilly, director of AARP’s health and family legislative team. “These bills will remove barriers that have prevented lower-cost generic drugs from entering the market.” AARP’s campaign promotes four solutions to the escalating prices of prescription drugs: ; ; ; and , such as the ones these two generics bills attack.
“When brand-name, generic and biologic drugmakers enter into agreements to keep more affordable medicines out of the marketplace, all of us are left to pay the price,” Grassley said in introducing the bill. “Competition among drug makers is critical to lowering the price of prescription medications.”
Bipartisan Bills in Congress Would Increase Access to Generics
AARP supports measures that would help lower exorbitant prescription drug prices
Getty Images Legislation working its way through Congress would deter brand-name pharmaceutical companies from making it more difficult for generic companies to make lower-priced versions of their products and outlaw deals some drugmakers strike to delay the creation of generic medicines.The Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act targets anticompetitive behavior by brand-name drugmakers that inhibits the development of competing generics. This bill has been introduced in both the House of Representatives and the Senate. Get instant access to members-only products and hundreds of discounts, a free second membership, and a subscription to AARP the Magazine. A separate measure would end the use of so-called pay-for-delay deals in which brand-name companies pay generic manufacturers to delay launching a lower-priced version of their product. “AARP has made expanding access to generics one of our federal priorities in our prescription drug campaign,” says Megan O’Reilly, director of AARP’s health and family legislative team. “These bills will remove barriers that have prevented lower-cost generic drugs from entering the market.” AARP’s campaign promotes four solutions to the escalating prices of prescription drugs: ; ; ; and , such as the ones these two generics bills attack.
Pay-for-delay bills
AARP Membership — $12 for your first year when you sign up for Automatic Renewal Get instant access to members-only products and hundreds of discounts, a free second membership, and a subscription to AARP the Magazine. Flowers & Gifts 25% off sitewide and 30% off select items See more Flowers & Gifts offers > In the House, the Protecting Consumer Access to Generic Drugs Act of 2019 (HR 1499) was authored by Rep. Bobby L. Rush (D-Ill.) and was referred to the Energy and Commerce and Judiciary committees. Energy and Commerce, led by Chairman Frank Pallone Jr. (D-N.J.) and ranking Republican member Greg Walden (R-Ore.), had a subcommittee hearing on the measure last week. The Senate bill — the Preserve Access to Affordable Generics and Biosimilars Act (S 64) — was introduced by Sens. Chuck Grassley, R-Iowa, and Amy Klobuchar, D-Minn. Biosimilars are the generic versions of biologic drugs, which are made from living organisms. This bill was referred to the Senate Judiciary Committee, where Grassley and Klobuchar are members.“When brand-name, generic and biologic drugmakers enter into agreements to keep more affordable medicines out of the marketplace, all of us are left to pay the price,” Grassley said in introducing the bill. “Competition among drug makers is critical to lowering the price of prescription medications.”